• Exozymes closed an underwritten public offering raising about USD 5.95 million in gross proceeds from common stock and warrants.
• Issued 330,575 units; each unit included two common shares priced at USD 8.99 plus one warrant priced at USD 0.02.
• Warrants become exercisable one year from issuance at USD 11.24 per share; expire five years from issuance.
• Proceeds earmarked for N-trans-caffeoyltyramine development and commercialization, broader pipeline work, R&D, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606171610ACCESSWRNAPR_____1178706) on June 17, 2026, and is solely responsible for the information contained therein.